HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV

Shenzhen Geno-Immune Medical Institute

Status and phase: Unknown; Phase 2; Phase 1

Conditions: Human Papilloma Virus

Treatments: Biological: HPV-CTLs

Study type: Interventional

Funder types: Other

Identifiers

NCT03351855

GIMI-IRB-17020

Details and patient eligibility

About

The purpose of this clinical trial is to evaluate the safety and efficacy of IV-infused autologous or allogenic HPV-CTLs.

Full description

Human papilloma viruses (HPV) have been consistently implicated in causing cervical cancer especially those high-risk types (HPV 16, 18, 31, 45). Around 50-80% of women are infected by HPV within their whole lives. The current treatment of HPV-positive mainly includes drug, cryotherapy, laser, microwave, surgery and so on. Some treatments are convenient, but easy to cause pain or infection and there is still a greater risk of recurrence after treatment.

Adoptive immunotherapy with cytotoxic T lymphocytes (CTLs) reactive with specific viral antigens has proven to be effective. Here, the investigators aim to evaluate the safety and efficacy of multiple infusions of HPV specific cytotoxic T lymphocytes cells in patients.

Enrollment: 100 estimated patients

Sex: All

Ages: 6 months to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Written, informed consent obtained prior to any study-specific procedures.

2. Evidence of HPV virus activation (viral DNA) or high risk of HPV infection.

3. Not suitable for routine treatment or invalid to antiviral drugs.

4. Patients with viral disease symptoms and confirmed by biopsy, regardless of the level of virus DNA.

5. Age less than 75 years.

6. Did not use Penicillin or β-lactam antibiotics, or the lowest dose of other antibiotics.

7. Initial hematopoietic reconstitution: neutrophils (ANC) ≥ 1,000/mm^3, platelet (PLT) ≥ 1,000/mm^3.

8. Proper renal and hepatic functions (ULN denotes "upper limit of normal range"): Creatinine ≤ 2*ULN, Bilirubin ≤ 2*ULN, SGOT/ SGPT ≤ 3*ULN.

9. If HPV-CTL is not from the patient's own, then the provider of HPV-CTL needs to meet the following criteria:

   • did not receive chemotherapy or radiotherapy within 4 weeks prior to blood collection, and did not take any steroids for the previous week, did not use Penicillin or β-lactam antibiotics, or the lowest dose of other antibiotics.
   • white blood cells ≥ 3,500 / μl, lymphocytes ≥ 750 / μl.

10. Human immunodeficiency virus (HIV) test was negative.

Exclusion criteria

1. Subject or the donor of BMT recipient infected with HCV (HCV antibody positive), HBV (HBsAg positive), HIV (HIV antibody positive), HTLV (HTLV antibody positive), Treponema pallidum antibody positive or TB culture positive.
2. Subject is albumin-intolerant.
3. Subject with life expectancy less than 8 weeks.
4. Subject participated in other investigational somatic cell therapies within past 30 days.
5. Subject with positive pregnancy test result.

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

100 participants in 1 patient group

HPV-CTLs

Experimental group

Description:

Autologous or allogenic HPV specific cytotoxic lymphocytes

Treatment:

Biological: HPV-CTLs